0000000000249662

AUTHOR

Cristiano A. Köhler

showing 9 related works from this author

Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analys…

2017

People with severe mental illness (SMI) – schizophrenia, bipolar disorder and major depressive disorder – appear at risk for cardiovascular disease (CVD), but a comprehensive meta-analysis is lacking. We conducted a large-scale meta-analysis assessing the prevalence and incidence of CVD; coronary heart disease; stroke, transient ischemic attack or cerebrovascular disease; congestive heart failure; peripheral vascular disease; and CVD-related death in SMI patients (N=3,211,768) versus controls (N=113,383,368) (92 studies). The pooled CVD prevalence in SMI patients (mean age 50 years) was 9.9% (95% CI: 7.4-13.3). Adjusting for a median of seven confounders, patients had significantly higher o…

medicine.medical_specialtyCardiovascular disease; bipolar disorder; cerebrovascular disease; congestive heart failure; coronary heart disease; major depression; premature mortality; schizophrenia; severe mental illness03 medical and health sciences0302 clinical medicinesevere mental illnessMedicineCardiovascular disease severe mental illness schizophrenia bipolar disorder major depression coronary heart disease cerebrovascular disease congestive heart failure premature mortalitycoronary heart diseasePsychiatrybipolar disorderFramingham Risk Scorebusiness.industryVascular diseaseIncidence (epidemiology)Hazard ratioCorrectionOdds ratiomedicine.diseaseCardiovascular disease030227 psychiatrycerebrovascular diseaseschizophreniaPsychiatry and Mental healthcongestive heart failurepremature mortalityHeart failureMajor depressive disorderPshychiatric Mental Healthbusinessmajor depressionBody mass index030217 neurology & neurosurgery
researchProduct

The relationship between genetic risk variants with brain structure and function in bipolar disorder: A systematic review of genetic-neuroimaging stu…

2017

Genetic-neuroimaging paradigms could provide insights regarding the pathophysiology of bipolar disorder (BD). Nevertheless, findings have been inconsistent across studies. A systematic review of gene-imaging studies involving individuals with BD was conducted across electronic major databases from inception until January 9th, 2017. Forty-four studies met eligibility criteria (N = 2122 BD participants). Twenty-six gene variants were investigated across candidate gene studies and 4 studies used a genome-wide association approach. Replicated evidence (i.e. in >2 studies) suggests that individuals with BD carrying the BDNF Val66Met risk allele could have reduced hippocampal volumes compared …

Transtorno BipolarCandidate genediffusion tensor imagingvoxel based morphometryBipolar disorderBipolar disorder Genetic polymorphisms Neuroimaging Magnetic resonance imaging Functional MRI Diffusion tensor imagingvoxel based morphometryCognitive NeuroscienceBrain Structure and FunctionGenome-wide association studyNeuroimagingComputational biologyGenetic polymorphismsFaculty of Social Sciences03 medical and health sciencesDISC1Behavioral Neuroscience0302 clinical medicineMagnetic resonance imagingNeuroimaginggenetic polymorphisms/dk/atira/pure/core/keywords/FacultyOfSocialSciencesImatges per ressonància magnèticamedicineHumansManic-depressive illnessANK3Bipolar disorderCervellNeuroimagemDiffusion tensor imagingvoxel based morphometryFunctional MRIGenetic polymorphismneuroimagingTrastorn bipolarbiologyBipolar disorder; Diffusion tensor imagingvoxel based morphometry; Functional MRI; Genetic polymorphisms; Magnetic resonance imaging; Neuroimaging; Neuropsychology and Physiological Psychology; Cognitive Neuroscience; Behavioral NeuroscienceReproducibility of ResultsBrainmedicine.disease030227 psychiatryNeuropsychology and Physiological Psychology5-HTTLPRbiology.proteinfunctional MRIImagem por Ressonância MagnéticaPsychologyNeuroscience030217 neurology & neurosurgeryHumanGenome-Wide Association Study
researchProduct

Peripheral Alterations in Cytokine and Chemokine Levels After Antidepressant Drug Treatment for Major Depressive Disorder: Systematic Review and Meta…

2017

Mounting evidence suggests that aberrations in immune-inflammatory pathways contribute to the pathophysiology of major depressive disorder (MDD), and individuals with MDD may have elevated levels of predominantly pro-inflammatory cytokines and C-reactive protein. In addition, previous meta-analyses suggest that antidepressant drug treatment may decrease peripheral levels of interleukin-1 beta (IL-1β) and IL-6. Recently, several new studies examining the effect of antidepressants on these cytokines have been published, and so we performed an updated meta-analysis of studies that measured peripheral levels of cytokines and chemokines during antidepressant treatment in patients with MDD. The P…

epressionChemokinemedicine.drug_classmedicine.medical_treatmentNeuroscience (miscellaneous)InflammationAntidepressantPharmacology03 medical and health sciencesCellular and Molecular Neuroscience0302 clinical medicinemedicineHumansMeta-analysiCytokineInflammationDepressive Disorder MajorbiologyDepressionbusiness.industrymedicine.diseaseReceptor antagonistAntidepressive Agents030227 psychiatryMeta-analysisCytokineTreatment OutcomeAntidepressant; Chemokines; Cytokines; Depression; Inflammation; Meta-analysis; Cellular and Molecular NeuroscienceNeurologyChemokineMeta-analysisbiology.proteinCytokinesMajor depressive disorderAntidepressantTumor necrosis factor alphamedicine.symptomChemokinesbusiness030217 neurology & neurosurgeryMolecular neurobiology
researchProduct

Lifetime self-reported arthritis is associated with elevated levels of mental health burden: A multi-national cross sectional study across 46 low- an…

2017

Population-based studies investigating the relationship of arthritis with mental health outcomes are lacking, particularly among low- and middle-income countries (LMICs). We investigated the relationship between arthritis and mental health (depression spectrum, psychosis spectrum, anxiety, sleep disturbances and stress) across community-dwelling adults aged ≥18 years across 46 countries from the World Health Survey. Symptoms of psychosis and depression were established using questions from the Mental Health Composite International Diagnostic Interview. Severity of anxiety, sleep problems, and stress sensitivity over the preceding 30 days were self-reported. Self-report lifetime history of a…

MaleCross-sectional studyPsychological interventionArthritisComorbidityGlobal Health0302 clinical medicineQUALITY-OF-LIFEOdds RatioPrevalencePublic Health Surveillance030212 general & internal medicineGENERAL-POPULATIONINFECTED PATIENTSeducation.field_of_studyMultidisciplinaryQRMiddle Aged3. Good healthMental HealthDEPRESSIVE SYMPTOMSIncomeMedicineAnxietyFemalemedicine.symptomAdultmedicine.medical_specialtySciencePopulationArticleYoung Adult03 medical and health sciencesmedicineHumansPsychiatryeducationDeveloping CountriesSLEEP PROBLEMSbusiness.industryArthritisOdds ratioGLOBAL BURDENSTRESS SENSITIVITYmedicine.diseaseComorbidityMental healthPSYCHOTIC EXPERIENCESRHEUMATOID-ARTHRITISCross-Sectional StudiesPHYSICAL-ACTIVITYSocial ClassSelf Reportbusiness030217 neurology & neurosurgeryScientific Reports
researchProduct

Peripheral cytokine and chemokine alterations in depression: a meta-analysis of 82 studies

2017

Objective: To conduct a systematic review and meta-analysis of studies that measured cytokine and chemokine levels in individuals with major depressive disorder (MDD) compared to healthy controls (HCs). Method: The PubMed/MEDLINE, EMBASE, and PsycINFO databases were searched up until May 30, 2016. Effect sizes were estimated with random-effects models. Result: Eighty-two studies comprising 3212 participants with MDD and 2798 HCs met inclusion criteria. Peripheral levels of interleukin-6 (IL-6), tumor necrosis factor (TNF)-alpha, IL-10, the soluble IL-2 receptor, C-C chemokine ligand 2, IL-13, IL-18, IL-12, the IL-1 receptor antagonist, and the soluble TNF receptor 2 were elevated in patient…

MaleChemokinePeripheral cytokinemedicine.drug_classmedicine.medical_treatmentInflammationchemokinesbehavioral disciplines and activities03 medical and health sciences0302 clinical medicinemental disordersHumansMedicineReceptorDepressive Disorder Majorbiologybusiness.industrychemokines; cytokines; depression; inflammation; meta-analysis; Psychiatry and Mental HealthReceptor antagonistmedicine.diseasecytokines030227 psychiatrymeta-analysisCytokineinflammationPsychiatry and Mental HealthMeta-analysisImmunologydepressionbiology.proteinMajor depressive disorderFemaleTumor necrosis factor alphamedicine.symptombusiness030217 neurology & neurosurgery
researchProduct

Lurasidone in the Treatment of Bipolar Depression: Systematic Review of Systematic Reviews

2017

Introduction. A burgeoning number of systematic reviews considering lurasidone in the treatment of bipolar depression have occurred since its Food and Drug Administration extended approval in 2013. While a paucity of available quantitative evidence still precludes preliminary meta-analysis on the matter, the present quality assessment of systematic review of systematic reviews, nonetheless, aims at highlighting current essential information on the topic. Methods. Both published and unpublished systematic reviews about lurasidone mono- or adjunctive therapy in the treatment of bipolar depression were searched by two independent authors inquiring PubMed/Cochrane/Embase/Scopus from inception u…

Genetics and Molecular Biology (all)Transtorno Bipolarmedicine.medical_specialtyBipolar DisorderImmunology and Microbiology (all)ConcordanceDrug profileAlternative medicineMEDLINElcsh:MedicineReview ArticleBiochemistryGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciencesLurasidone Hydrochloride0302 clinical medicineImmunology and Microbiology (all); Biochemistry Genetics and Molecular Biology (all)medicineBipolar DepressionHumansPsychiatryDrug ApprovalDepression (differential diagnoses)LurasidoneGeneral Immunology and Microbiologybusiness.industrylcsh:RGeneral Medicine030227 psychiatrySystematic reviewTolerabilityDepressãobusiness030217 neurology & neurosurgerymedicine.drugLurasidone
researchProduct

Perceived stress and smoking across 41 countries: A global perspective across Europe, Africa, Asia and the Americas

2017

Within recent years, there has been a seismic shift in smoking rates from high-income to low- and middle-income countries (LMICs). Evidence indicates that perceived stress may comprise a barrier for smoking cessation, but little is known about the association of perceived stress and smoking in LMICs. We conducted a cross-sectional, community-based study comprising 217,561 people [mean age 38.5 (SD = 16.1) years, 49.4% males]. A perceived stress score [range 2 (lowest-stress) 10 (highest-stress)] was computed from the Perceived Stress Scale. Multivariable logistic regression analyses were conducted. In the overall sample, a one-unit increase in perceived-stress resulted in a 5% increased odd…

GerontologyAdultMalemedicine.medical_specialtyMultivariate analysisAsiaCross-sectional studySciencemedicine.medical_treatmentDeveloping countryPerceived Stress ScaleLogistic regressionArticle03 medical and health sciences0302 clinical medicineMIDDLE-INCOME COUNTRIESmedicineHumansTOBACCO SMOKING030212 general & internal medicineProspective cohort studyDeveloping CountriesPovertyAgedHEALTH SURVEYSMultidisciplinarybusiness.industryPublic healthQRMiddle AgedEuropeCross-Sectional StudiesLogistic ModelsAfricaMultivariate AnalysisIncomeMedicineSmoking cessationFemalePerceptionSmoking CessationCIGARETTE-SMOKINGAmericasbusiness030217 neurology & neurosurgeryStress PsychologicalDemography
researchProduct

Mapping risk factors for depression across the lifespan: An umbrella review of evidence from meta-analyses and Mendelian randomization studies

2018

The development of depression may involve a complex interplay of environmental and genetic risk factors. PubMed and PsycInfo databases were searched from inception through August 3, 2017, to identify meta-analyses and Mendelian randomization (MR) studies of environmental risk factors associated with depression. For each eligible meta-analysis, we estimated the summary effect size and its 95% confidence interval (CI) by random-effects modeling, the 95% prediction interval, heterogeneity with I 2 , and evidence of small-study effects and excess significance bias. Seventy meta-analytic reviews met the eligibility criteria and provided 134 meta-analyses for associations from 1283 primary studie…

MOOD DISORDERSPUBLISHED LITERATURELongevityPsycINFORisk Assessment17 Psychology And Cognitive Sciences03 medical and health sciencesUmbrella review0302 clinical medicineMendelian randomizationIMPAIRED GLUCOSE-METABOLISMmedicineHumansOLDER-ADULTSBiological PsychiatryDepression (differential diagnoses)PsychiatryScience & Technologybusiness.industryDepressionPreventiongenetic risk factorPrediction intervalMAJOR DEPRESSION11 Medical And Health SciencesMendelian Randomization Analysismedicine.diseaseADEQUATE PARENTAL CAREMental healthConfidence intervalADULT DEPRESSION030227 psychiatryDepression; Meta-analyses; Prevention; Psychiatry; Risk factors; Umbrella reviewSYSTEMATIC REVIEWSPsychiatry and Mental healthSystematic reviewMood disordersRisk factorsMeta-analysesINDIVIDUAL PARTICIPANT DATAbusinessLife Sciences & BiomedicineMENTAL-HEALTH030217 neurology & neurosurgeryDemography
researchProduct

Systematic review and exploratory meta-analysis of the efficacy, safety, and biological effects of psychostimulants and atomoxetine in patients with …

2019

ObjectiveOur aim was to summarize the efficacy and safety of atomoxetine, amphetamines, and methylphenidate in schizophrenia.MethodsWe undertook a systematic review, searching PubMed/Scopus/Clinicaltrials.gov for double-blind, randomized, placebo-controlled studies of psychostimulants or atomoxetine in schizophrenia published up to 1 January 2017. A meta-analysis of outcomes reported in two or more studies is presented.ResultsWe included 22 studies investigating therapeutic effects of stimulants (k=14) or measuring symptomatic worsening/relapse prediction after stimulant challenge (k=6). Six studies of these two groups plus one additional study investigated biological effects of psychostimu…

safetymedicine.medical_specialtyPsychosismedicine.medical_treatmentefficacyamphetamineSchizoaffective disorderAtomoxetine Hydrochloridemeta-analysi03 medical and health sciencesExecutive Function0302 clinical medicinesystematic reviewInternal medicinemedicineHumansAttentionAmphetamineProblem Solvingbusiness.industryMethylphenidateAtomoxetineAmphetaminesrelapse predictorstimulantmedicine.disease030227 psychiatryStimulantPsychiatry and Mental healthMemory Short-Termamphetamine atomoxetine efficacy meta-analysis methylphenidate relapse predictor safety schizophrenia stimulants systematicn reviewPsychotic DisordersSchizophreniaMeta-analysisMethylphenidateSchizophreniaNeurology (clinical)businessatomoxetine030217 neurology & neurosurgerymedicine.drugAntipsychotic Agents
researchProduct